Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Launched by PFIZER · Dec 6, 2005
Trial Information
Current as of August 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrollment in Stage 1 of Study A3921009 and have completed 6-months of treatment with trial medications (CP-690,550 or tacrolimus)
- • Recipient of a first-time kidney transplant
- Exclusion Criteria:
- • Subject with any untreated condition that may affect drug absorption (eg, gastrectomy or clinically significant diabetic gastroenteropathy).
- • Subjects who are on the waiting list for a second kidney transplant or any non-renal organ transplants.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Chicago, Illinois, United States
Dallas, Texas, United States
Stanford, California, United States
Milwaukee, Wisconsin, United States
San Diego, California, United States
St. Louis, Missouri, United States
San Francisco, California, United States
Aurora, Colorado, United States
Los Angeles, California, United States
Portland, Oregon, United States
Portland, Oregon, United States
San Diego, California, United States
New York, New York, United States
Los Angeles, California, United States
Los Angeles, California, United States
Palo Alto, California, United States
San Diego, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Chicago, Illinois, United States
New York, New York, United States
New York, New York, United States
Portland, Oregon, United States
Dallas, Texas, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials